Scandinavian ChemoTech AB Series B Total Liabilities
Scandinavian ChemoTech AB Series B total liabilities. Based on the latest financial reports, Scandinavian ChemoTech AB Series B (CMOTEC-B) has total liabilities worth Skr9.49 Million SEK (≈ $1.02 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of Scandinavian ChemoTech AB Series B to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Scandinavian ChemoTech AB Series B (2014–2025)
Total liabilities of Scandinavian ChemoTech AB Series B from 2014 to 2025. This chart illustrates how Scandinavian ChemoTech AB Series B's total liabilities have evolved over time, based on quarterly financial data.
Scandinavian ChemoTech AB Series B Competitors by Total Liabilities
The table below lists competitors of Scandinavian ChemoTech AB Series B ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Metal Hawk Ltd
AU:MHK
|
Australia | AU$118.96K |
|
Omineca Mining and Metals Ltd
V:OMM
|
Canada | CA$13.59 Million |
|
Swift Networks Group Ltd
AU:SW1
|
Australia | AU$16.14 Million |
|
Palash Securities Limited
NSE:PALASHSECU
|
India | Rs404.79 Million |
|
Holand og Setskog Sparebank
OL:HSPG
|
Norway | Nkr8.13 Billion |
|
Akkhie Prakarn Public Company Limited
BK:AKP
|
Thailand | ฿97.27 Million |
|
Fourth-Link Inc.
KQ:056730
|
Korea | ₩14.89 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Scandinavian ChemoTech AB Series B's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Scandinavian ChemoTech AB Series B asset portfolio.
Liquidity & Leverage Metrics
Scandinavian ChemoTech AB Series B Total Liabilities Ratios Explained
Scandinavian ChemoTech AB Series B total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 6.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.86 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scandinavian ChemoTech AB Series B's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scandinavian ChemoTech AB Series B (2014–2025)
The table below shows the annual total liabilities of Scandinavian ChemoTech AB Series B from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr10.01 Million ≈ $1.08 Million |
+35.32% |
| 2024-12-31 | Skr7.40 Million ≈ $796.36K |
+92.81% |
| 2023-12-31 | Skr3.84 Million ≈ $413.03K |
-50.21% |
| 2022-12-31 | Skr7.71 Million ≈ $829.61K |
+307.24% |
| 2021-12-31 | Skr1.89 Million ≈ $203.72K |
-71.98% |
| 2020-12-31 | Skr6.75 Million ≈ $726.95K |
-12.95% |
| 2019-12-31 | Skr7.76 Million ≈ $835.10K |
+235.50% |
| 2018-12-31 | Skr2.31 Million ≈ $248.92K |
-9.52% |
| 2017-12-31 | Skr2.56 Million ≈ $275.11K |
+13.94% |
| 2016-12-31 | Skr2.24 Million ≈ $241.46K |
-61.21% |
| 2015-12-31 | Skr5.78 Million ≈ $622.47K |
+29367.34% |
| 2014-12-31 | Skr19.63K ≈ $2.11K |
-- |
About Scandinavian ChemoTech AB Series B
Neem's Hill AB, a medical technology company, engages in the development of patented treatment alternatives for humans and animals with cancer in Sweden and internationally. It offers IQwave, an electroporation that generates tumor-specific electrical stimulation for the treatment of solid superficial tumors of various sizes and locations. Neem's Hill AB was formerly known as Scandinavian ChemoTe… Read more